Analytical Data
-
Gene name
PTGIS
- Application
-
Alternative Names
PGIS; CYP8A1; Prostacyclin Synthase; Prostacycline Synthetase; Prostagladin I2 Synthetase; PGI2 Synthetase; Cytochrome P450,Family 8,Subfamily A,Polypeptide 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16647
-
Expression Region
Met1~Pro500
-
Molecular Weight
61kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGIS (prostaglandin I synthase) is an important enzyme involved in the biosynthesis of prostaglandin I2 (prostacyclin), a potent vasodilator and inhibitor of platelet aggregation. Research on PTGIS has gained attention due to its significant role in cardiovascular health and disease, particularly in conditions such as hypertension, atherosclerosis, and thrombosis. The enzyme is primarily expressed in endothelial cells and is essential for maintaining vascular homeostasis. Given the therapeutic potential of targeted prostacyclin pathways, scientists have focused on characterizing PTGIS at a molecular level, studying its structure, function, and regulatory mechanisms. The production of recombinant PTGIS proteins has enabled researchers to investigate enzyme kinetics, interactions with other proteins, and the effects of post-translational modifications. Furthermore, structural studies using techniques like X-ray crystallography and NMR spectroscopy have provided insights into the enzyme's active site and substrate specificity. Understanding PTGIS's function and regulation at a detailed level may offer new avenues for developing pharmacological agents that harness its protective effects against cardiovascular diseases. As a result, PTGIS is not only a critical focus of basic science research but also holds promise for the development of novel therapeutic strategies aimed at improving vascular health.
